Table 1.

Study cohort characteristics. Values are mean ± standard deviation, median (IQR) or n/N (%).

		FVC Stratification		Traffic Light Stratification
	All	FVC >50	FVC ≤50	Green	Amber	Red
n	107	72	26	20	20	25
Age at onset, years	64.2 ± 11.85	64.2 ± 11.6	63.8 ± 13.1	64.6 ± 11.2	65.1 ± 14.2	68.1 ± 9.7
Bulbar onset	44 (41%)	31 (43%)	11 (42%)	11 (55%)	10 (50%)	6 (17%)
Disease progression rate,  ALSFRS points per month	0.59 ± 0.43	0.58 ± 0.44	0.63 ± 0.44	0.53 ± 0.48	0.59 ± 0.36	0.56 ± 0.25
Total disease duration, days	871 (594–1212), n = 82	886 (626–1299), n = 59	741.5 (478–1112), n = 20	894 (745–1177), n = 14	759 (590–1259), n = 16	755 (518–1008), n = 15
Disease duration prior to PEG, days	584 (399–868)	562 (396–864)	765 (453–868)	576 (406–1005)	584 (397–894)	777 (453–931)
Pre-PEG FVC, %predicted	64 ± 22	73 ± 17	40 ± 9	80 ± 20	56 ± 17	48 ± 15
Midazolam dose, mg	3.0 (2.0–4.0)	3.0 (2.0–4.0)	2.0 (2.0–4.0)	3.0 (2.0–3.0)	2.0 (2.0–3.0)	2.0 (1.5–2.9)
Fentanyl dose, μg	50 (50–75)	50 (50–75)	50 (25–50)	50 (50–75)	50 (25–63)	50 (25–50)
Survival post-PEG, years	285 (129–434), n = 82	323 (194–484), n = 59	165 (54–202), n = 20	333 (259–434), n = 14	224 (165–315), n = 16	166 (91–317), n = 15
30-d mortality	4/107 (4%)	0/72 (0%)	4/26 (15%)	0/20 (0%)	0/20 (0%)	2/25 (8%)
Six-month mortality	17/107 (16%)	10/72 (14%)	7/26 (27%)	1/20 (5%)	4/20 (20%)	4/25 (16%)